Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 03:52:31 17/07/2024 pm IST			5-day change	1st Jan Change
275 ^CHF	+6.22%		+9.88%	+11.90%

11:45am	Roche Obesity Pill Achieves Positive Results in Early-Stage Trial -- 2nd Update	DJ
10:56am	European shares slide as tech stocks weigh	RE

ROCHE HOLDINGS AG : Goldman Sachs reiterates its Sell rating

July 17, 2024 at 02:07 pm IST

James Quigley from Goldman Sachs retains his negative opinion on the stock with a Sell rating. The target price continues to be set at CHF 230.

Latest news about Roche Holding AG

Roche Obesity Pill Achieves Positive Results in Early-Stage Trial -- 2nd Update	03:15pm	DJ
European shares slide as tech stocks weigh	02:26pm	RE
ROCHE HOLDINGS AG : Goldman Sachs reiterates its Sell rating	02:07pm	ZD
Roche: share price rises following successful obesity trial	01:21pm	CF
Roche Obesity Pill Achieves Positive Results in Early-Stage Trial -- Update	12:05pm	DJ
Roche reports positive early results in obesity drug trial	11:43am	RE
Roche Obesity Pill Achieves Positive Results in Early-Stage Trial	11:00am	DJ
Roche's Obesity Drug Lowers Weight in Early-stage Study	10:52am	MT
Roche Holding AG Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People with Obesity	10:30am	CI
Roche Receives Canadian Approval for Early-stage Lung Cancer Treatment	09:55am	MT
ROCHE HOLDINGS AG : Sell rating from Goldman Sachs	15/07	ZD
ROCHE HOLDINGS AG : Gets a Neutral rating from Deutsche Bank	15/07	ZD
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating	11/07	ZD
DexCom, Inc. : A Must-Have Tool for Diabetes Care	10/07
Markets Powered by Alternating Current	10/07
ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating	10/07	ZD
ROCHE HOLDINGS AG : UBS gives a Neutral rating	10/07	ZD
SIX to Cap SLI Index Weight of Nestle, Novartis Roche, UBS	10/07	MT
Swiss Market Index Closes in the Red; Roche Rises	09/07	MT
Mixed feelings	09/07
ROCHE HOLDINGS AG : UBS remains Neutral	09/07	ZD
Roche: CE marking in diabetes monitoring	09/07	CF
Roche Secures CE Mark for AI-powered Continuous Glucose Monitoring Device	09/07	MT
Roche Receives CE Mark for Its AI-Enabled Continuous Glucose Monitoring Solution Offering Critical Predictions to People Living with Diabetes	09/07	CI
Roche Secures FDA Nod to Relaunch Susvimo in US After Recall	09/07	MT

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

23/07/2024 - American Society of Retina Specialists Meeting

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 09:20 pm IST

Obesity: Roche joins the battle

December 04, 2023 at 09:18 pm IST

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

258.9 CHF

Average target price

274 CHF

Spread / Average Target

+5.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	+11.90%	23TCr
ELI LILLY AND COMPANY	+61.53%	85TCr
NOVO NORDISK A/S	+33.48%	63TCr
JOHNSON & JOHNSON	-3.66%	36TCr
MERCK & CO., INC.	+15.06%	32TCr
ABBVIE INC.	+9.18%	30TCr
NOVARTIS AG	+16.24%	23TCr
AMGEN INC.	+15.67%	18TCr
PFIZER, INC.	+2.47%	17TCr
SANOFI	+2.48%	13TCr

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : Goldman Sachs reiterates its Sell rating

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals